Carvedilol: a review of its use in chronic heart failure.

摘要: Carvedilol (Dilatrend) blocks beta(1)-, beta(2)- and alpha(1)-adrenoceptors, has antioxidant antiproliferative effects. improved left ventricular ejection fraction (LVEF) in patients with chronic heart failure (CHF) numerous studies. Moreover, significantly greater increases from baseline LVEF were seen carvedilol than metoprolol a double-blind, randomised study meta-analysis. also reversed or attenuated remodelling CHF those dysfunction after acute myocardial infarction (MI). Combined analysis of studies the US Heart Failure Trials Program (patients had varying severities CHF; n = 1094) revealed that mortality was lower placebo recipients. In addition, risk hospitalisation for any cardiovascular cause placebo. Mortality mild to severe Or Metoprolol European Trial (COMET) [n 3029]. The Prospective Randomised Cumulative Survival (COPERNICUS) trial (n 2289) demonstrated compared placebo, associated significant reductions all-cause combined endpoint death reason CHF. All-cause reduced who received addition conventional therapy plus Post-Infarct Control LV Dysfunction (CAPRICORN) (enrolling 1959 following MI). generally well tolerated Adverse events alpha- beta-blocking effects drug occurred more commonly whereas recipients likely experience worsening failure. conclusion, alpha(1)-adrenoceptors unique pharmacological profile. It is thought additional properties (e.g. effects) contribute its beneficial improves function reduces morbidity CHF, should be considered standard treatment option this setting. Administering attenuates MI. suggesting may preferred beta-blocker.